Fisher Scientific International Inc
Fisher Scientific International — Merger or Acquisition (June 2004)
20 slides from Fisher Scientific International's merger presentation, Jun 1, 2004

Slide 1: The World Leader in Serving Science
The World Leader in Serving Science June 2004

Slide 2: Safe Harbor and Regulation G Statement
Safe Harbor and Regulation G Statement The statements in this presentation which are not historical facts or information are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the outcome to be materially different. Certain of these risks an

Slide 3: Fisher at a Glance
Fisher at a Glance - Founded in 1902 Proprietary 60% Distributed 40% (80% Consumable) * Includes effect of the Apogent transaction. 350,000 customers Global scientific research $20 U.S. clinical laboratory $10 2004E Sales $4.6B EPS $2.81 Growing Markets ($ Bils) Favorable market dynamics Extensive L

Slide 4: Diverse Customer Base
No Customer > 2.5% of Sales Diverse Customer Base Pharma 0.23 Hospitals 0.17 Reference Labs / Other 0.08 Other 0.33 Medical Research 0.08 Colleges and Universities 0.11

Slide 5: Market Dynamics are Favorable
9 Market Dynamics are Favorable Pressure on drug development costs Aging population R&D spending steadily increasing Growth in homeland security spending Demand for low cost solutions More diagnostic testing Research market growing Demand for safety related products

Slide 6: Scientific Research Market
Scientific Research Market Leadership position Global Market Size: $20 Billion Growth Rate: 5 - 8% U.S. R&D Spending CAGR: 9% 1960 1965 1970 1975 1980 1985 1990 1995 2003 (Excl. Defense and Electronics) ($ in billions) Sources: Laboratory Products Association, SDI Inc., SAI, and management estimates

Slide 7: Clinical Lab Market
Clinical Lab Market Leadership position U.S. Market Size: $9.5 Billion Growth Rate: 4 - 5% Number of IVD Tests (Test Per Person) IVD Tests (in Bils) 1989 1993 1998 2003 2008 East 13.3 14.5 16.5 19.1 22 3.3 3.8 4.5 5.4 6.5 Sources: The Freedonia Group and management estimates.

Slide 8: Company Capabilities
Premier brands Industry-leading sales force Globally integrated supply chain Company Capabilities

Slide 9: Company Capabilities: Premier Brands
100 years of serving science Broad portfolio of proprietary products Unmatched service offering Company Capabilities Premier Brands Distributed Products 0.4 Self-Manufactured 0.6

Slide 10: Industry-Leading Sales Force
1,500 sales reps 1,200 customer service reps Industry-Leading Sales Force Company Capabilities Supply chain solutions 800* life science, chemical and technical specialists End-user sales and support * Includes effect of Apogent transaction.

Slide 11: Globally Integrated Supply Chain
Continually invest in leading edge technology Collaborate with our suppliers to drive supply chain efficiencies Company Capabilities Globally Integrated Supply Chain Provide customers with customized supply chain solutions

Slide 12: Reduced Investment in Working Capital
1998 1999 2000 2001 2002 2003 East 0.131 0.112 0.093 0.091 0.086 0.077 * Excludes impact of Perbio acquisition. Note: Working capital is defined as the average balance of the last four quarters of receivables plus inventories less accounts payable. As a Percentage of Sales * Company Capabilities Red

Slide 13: Growth Strategy
Growth Strategy 25 Increase proprietary product and service offering Capitalize on high growth life science market Increase earnings and cash flow growth

Slide 14: Apogent Transaction Benefits
Apogent Transaction Benefits Enhances portfolio of proprietary products and services Increases Fisher's life science footprint to $1.1 billion Strengthens Fisher's healthcare business Provides significant cost savings opportunities Increases cash flow generation Apogent - A perfect fit

Slide 15: Sales and Earnings Per Share Growth
Sales and Earnings Per Share Growth 2000 2001 2002 2003 2004F* 2005F* * Midpoint of management estimates and assumes Apogent transaction closes in early 3rd quarter, 2004. Sales exclude the impact of foreign exchange. EPS exclude goodwill amortization, restructuring and nonrecurring expenses. CAGR:

Slide 16: Strong Free Cash Flow
Strong Free Cash Flow 2000 2001 2002 2003 2004F 2005F ($ in millions) * Midpoint of management estimates and assumes Apogent transaction closes in early 3rd quarter, 2004. Free cash flow is cash from operations less capital expenditures. Memo: Debt-to-EBITDA 4.5x 3.5x 3.0x 3.6x 3.1x N/A * *

Slide 17: Investment Highlights
Investment Highlights Strong earnings and cash flow growth Favorable market dynamics Significant margin enhancement opportunities Strong management team

Slide 18: Questions and Answers
Questions and Answers

Slide 19: Supplementary Financial Information
(in millions, except per share amounts) Supplementary Financial Information

Slide 20: Additional Information
Additional Information In connection with the proposed merger, Fisher Scientific and Apogent Technologies have on file relevant materials with the SEC, including an effective registration statement that contains a prospectus and a joint proxy statement. Investors and security holders are urged to, o
Source: SEC EDGAR · 425 filed Jun 1, 2004
More decks from Fisher Scientific International Inc
Merger or Acquisition (May 2006)23 slides · May 8, 2006
Lehman Brothers Ninth Annual Global Healthcare Conference 200619 slides · Mar 8, 2006
Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference 200612 slides · Feb 9, 2006
Goldman Sachs Twenty Sixth Annual Global Healthcare Conference 200511 slides · Jun 15, 2005
Banc of America Securities Health Care Conference 200511 slides · May 17, 2005
Baird Growth Stock Conference 200526 slides · May 12, 2005